How India Exports Saxagliptin to the World

In the United States, saxagliptin is marketed under the brand name Onglyza. The FDA approved the first Abbreviated New Drug Application (ANDA) for saxagliptin tablets (2.5 mg and 5 mg) submitted by Amneal Pharmaceuticals LLC on November 30, 2025. This approval signifies the availability of generic versions, potentially increasing market competition and affecting pricing dynamics. Given that 91.1% of India's saxagliptin exports are directed to the U.S., the entry of generics could influence export volumes and pricing strategies for Indian manufacturers.

As of March 2026, there are no active FDA import alerts or significant regulatory actions concerning saxagliptin. The primary regulatory pathway for saxagliptin involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug, Onglyza. With 30 active Indian exporters and a repeat buyer rate of 56.1%, maintaining compliance with FDA regulations is crucial to sustain and expand market presence in the U.S.

In the European Union, saxagliptin received marketing authorization under the brand name Onglyza on October 1, 2009. The European Medicines Agency (EMA) has not reported any significant regulatory actions affecting saxagliptin since its approval. The combination product Qtern, containing saxagliptin and dapagliflozin, was authorized on July 15, 2016. However, AstraZeneca withdrew an application to extend Qtern's use on April 3, 2018, indicating strategic adjustments in the product's market positioning.

In the United Kingdom, post-Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of medicines. Saxagliptin continues to be available, with regulatory requirements aligning closely with those of the EMA. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

As of March 2026, saxagliptin is not listed on the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone WHO Prequalification, a program that assesses the quality, safety, and efficacy of medicinal products. However, saxagliptin formulations are expected to comply with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure consistent quality across markets.

In India, saxagliptin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for saxagliptin as of March 2026, allowing market-driven pricing. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patent for saxagliptin expired in July 2023, opening the market to generic competition. This development has led to increased market entry by generic manufacturers, both domestically and internationally, influencing pricing and market dynamics.

In November 2025, the FDA approved the first generic version of saxagliptin tablets, marking a significant milestone in increasing accessibility and affordability of the medication. This approval is expected to impact export strategies for Indian manufacturers targeting the U.S. market.

In January 2026, the EMA updated the product information for Onglyza, incorporating new safety data related to cardiovascular risks. Manufacturers exporting to the EU must ensure that their product labeling reflects these updates to maintain compliance and market authorization.

In March 2026, the NPPA announced a review of pricing policies for DPP-4 inhibitors, including saxagliptin, to assess the need for potential price controls. While no immediate changes were implemented, manufacturers should monitor policy developments that could affect domestic pricing and export profitability.

These developments underscore the importance of staying informed about regulatory changes and market dynamics to effectively navigate the global pharmaceutical landscape for saxagliptin.

India's pharmaceutical industry, including the production of Saxagliptin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, particularly when Chinese manufacturers face operational disruptions. For instance, in 2018, environmental regulations led to the shutdown of over 140 API manufacturers in the Beijing-Tianjin-Hebei region due to effluent violations, causing global supply chain disruptions.

The Indian government has recognized this dependency as a strategic risk and, in 2020, introduced the Production Linked Incentive (PLI) scheme with an outlay of ₹6,940 crore to bolster domestic API and KSM production. Despite these efforts, the sector continues to grapple with challenges such as high manufacturing costs, stringent environmental regulations, and competition from countries like Vietnam investing in API production.

TransData Nexus's proprietary trade data from 2022 to 2026 reveals a high supplier concentration in Saxagliptin exports from India. The top five exporters account for 97.6% of the total export value, with MYLAN LABORATORIES LIMITED alone contributing 90.0%. Such concentration poses a significant single-source risk; any operational issues at these key suppliers could disrupt the entire supply chain.

The PLI scheme aims to mitigate these risks by encouraging diversification and enhancing domestic production capabilities. However, the effectiveness of this initiative in reducing supplier concentration remains to be fully realized, as the industry continues to face challenges in scaling up production and achieving cost competitiveness.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz following military conflicts disrupted global oil and LNG trade, leading to increased manufacturing and logistics costs. This disruption has had cascading effects on pharmaceutical manufacturing, including the production of Saxagliptin, due to heightened energy costs and logistical challenges. (pharmasource.global)

Additionally, the Red Sea conflict has posed risks to the supply of key pharmaceutical ingredients and chemicals, including APIs shipped from India to the US and Europe. These disruptions have led to fluctuating prices and potential delays in the delivery of pharmaceutical products. (pharmasource.global)

• Diversify Supplier Base: Encourage the development of multiple suppliers for Saxagliptin to reduce dependency on a single source.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to strengthen domestic API and KSM manufacturing capabilities.

• Strengthen Regulatory Compliance: Ensure adherence to environmental and quality standards to prevent operational disruptions.

• Develop Alternative Shipping Routes: Establish contingency plans for logistics to mitigate the impact of geopolitical disruptions on shipping lanes.

• Monitor Geopolitical Developments: Stay informed about international conflicts and their potential impact on supply chains to proactively address emerging risks.

RISK_LEVEL: HIGH